{"uid":"cap_sgz8TGh61KS5Odxp4KkSt","slug":"patentpulse-pharma-patent-cliff-generic-entry-analysis-fbd28723","name":"PatentPulse Pharma Patent Cliff & Generic Entry Analysis","description":"Pharma patent cliff / drug patent expiry / generic-entry analysis by drug name (e.g. Humira, Ozempic). Returns the patent expiry calendar, exclusivity timeline, and generic/biosimilar entry outlook across US, EU, and Japan, plus related USPTO patents. For IP and investment agents. Worldwide.","url":"https://patentpulse.theaslangroupllc.com/api/patent/cliff","method":"GET","headers":{},"bodySchema":{"type":"object","required":["drug"],"properties":{"drug":{"type":"string","description":"Drug name — generic or brand (e.g. humira, ozempic, keytruda)"},"lang":{"type":"string","description":"Response language"}}},"responseSchema":{"type":"json","example":{}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.15","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.15/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.15","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.15","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_d4LIbYN_rIR-awE-qD9iY","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.15","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns patent expiry calendar, exclusivity timeline, and generic/biosimilar entry outlook for a named drug across US, EU, and Japan, plus related USPTO patents.","exampleAgentPrompt":"Can you pull the full patent cliff and generic entry timeline for Ozempic — I need the patent expiry dates and biosimilar entry outlook across the US, EU, and Japan, plus any related USPTO patents?","exampleUseCases":[{"title":"Competitive drug launch timing analysis","prompt":"I'm evaluating when we can launch our generic competitor for Lipitor — can you get me the patent expiry calendar, exclusivity timelines, and biosimilar entry windows across US, EU, and Japan so we know our market entry window?"},{"title":"Pharma portfolio valuation and risk assessment","prompt":"We're acquiring a biotech company with three main drugs in their pipeline — can you pull the patent cliff analysis for Dupilumab, Rinvoq, and Baricitinib to show me remaining exclusivity periods and when generics could hit the market?"},{"title":"Investment thesis patent due diligence","prompt":"Before we commit capital to this pharma investment, I need the full IP picture on their lead asset — pull the patent expiry dates, generic entry timeline, and related USPTO patents across all major markets so we can model revenue cliff scenarios."}],"resultDescription":"Returns a structured patent expiry calendar showing key expiry dates by jurisdiction (US, EU, Japan), remaining exclusivity periods, projected generic and biosimilar entry windows, and a list of related USPTO patents for the queried drug — giving a complete IP exclusivity outlook for pharma investment or competitive analysis.","failureModes":["Drug name not recognized or not found in database — returns 404 or empty result","Drug has no patent data available for one or more jurisdictions — partial results returned","Ambiguous drug name (brand vs. generic INN) — may require more specific input","Rate limiting or payment failure via x402 — returns 402 Payment Required","Newly approved drugs with incomplete patent records — incomplete timeline data"],"whenToPreferThis":"Use this endpoint when you need pharmaceutical patent cliff analysis for a specific named drug, including multi-jurisdiction expiry dates (US, EU, Japan), biosimilar entry windows, and related USPTO patent lists. Prefer this over general patent search endpoints when the query is drug-name-driven and the goal is competitive generic/biosimilar entry forecasting or pharma investment due diligence rather than raw patent document retrieval.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-13T18:44:51.941Z","isFirstParty":false}